Version history
IBTR Risk Estimation
46
ASO score
Text
63/100
Reviews
0/100
Graphic
60/100
Other
0/100
App Rating
5
Votes
1
App Age
3m 1 day
Last Update
Dec 29, 2025
Compare with Category Top Apps
|
Metrics
|
Current App
|
Category Top Average
|
Difference
|
|---|---|---|---|
|
Rating
|
5
|
4.6
|
+9%
|
|
Number of Ratings (Voted)
|
1
|
65.9K
|
-100%
|
|
App Age
|
0y 3m
|
9y 3m
|
-97%
|
|
In-app Purchases Price
|
$0
|
$34
|
|
|
Update Frequency
|
58d
|
127d
|
-54%
|
|
Title Length
|
20
|
25
|
-20%
|
|
Subtitle Length
|
30
|
26
|
+15%
|
|
Description Length
|
1 367
|
2 673
|
-49%
|
|
Number of Screenshots
|
234
|
1373
|
-83
%
|
|
Size
|
8MB
|
280MB
|
-97
%
|
Category Ranking in United States
7 days
Last 7 days
Last 30 days
Last 90 days
Last 180 days
Last year
| Top | Jan 01, 2026 | Jan 08, 2026 |
|---|---|---|
|
No results were found!
|
||
| Top | Jan 01, 2026 | Jan 08, 2026 |
|---|---|---|
|
No results were found!
|
||
| Top | Jan 01, 2026 | Jan 08, 2026 |
|---|---|---|
|
No results were found!
|
||
| Top | Jan 01, 2026 | Jan 08, 2026 |
|---|---|---|
|
No results were found!
|
||
Ranking Keywords in United States
| Keywords | App Rank |
|---|
Analyze this and other apps using Asolytics tools
Text ASO
Title
(
Characters:
20
of 30
)
IBTR Risk Estimation
Subtitle
(
Characters:
30
of 30
)
Estimating IBTR and Tx Benefit
Description
(
Characters:
1367
of 4000
)
This application is a tool to estimate the risk of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery.
It provides 10-year IBTR risk estimates and treatment effects, based on clinicopathological factors (age, pathological T stage, grade, margin status, lymphovascular invasion, hormone receptor status, HER2 status) and treatment options (radiation therapy, chemotherapy, endocrine therapy, anti-HER2 therapy). The application is available for both iPhone and iPad.
The tool was developed using a Cox proportional hazards model from a multicenter cohort of 8,938 patients and calibrated with treatment effects from the EBCTCG meta-analysis. It is designed for use in shared decision-making between patients and clinicians, as well as for educational purposes. The development methodology was presented at the 2025 ASCO Annual Meeting (Abstract No. 575) and published in JCO Clinical Cancer Informatics (Sagara et al., 2025). For further details, please refer to the publication.
Disclaimer
This application is intended for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with the treating physician. The developers assume no legal responsibility for any outcomes resulting from the use of this application.}
Read more
Other
Additional Information
| Rating: | |
| Voted: | 1 |
| App Store Link: | |
| Website: | - |
| Email: | - |
| Privacy Policy: | |
| Categories: | Medical |
| Size: | 8MB |
| App Age: | 3 months 1 day |
| Release Date: | Oct 08, 2025 |
| Last Update: | Dec 29, 2025 |
| Version: | 1.5 |
Version history
1.5
Dec 29, 2025
Updated the Age Rating settings.
1.4
Oct 15, 2025
This version includes improvements to the IBTR risk estimation algorithm. Baseline risk and treatment effect visualization have been corrected for accuracy.